The importance of ER and HER2 activation to breast cancer growth is underlined by improved outcome for patients with advanced ER+ and HER2 amplified early breast cancers treated with an aromatase inhibitor and anti-HER2 therapy in concert [2,3]. Here, ESR1 is linked to breast cancer.